MEDACTA GROUP S.A. SF-,10

Medacta has announced the full commercial launch of the Mfinity Femoral System in the US. The hip implant offers multiple implant options and efficient instrumentation. The first procedures outside the US were performed in September 2026 in Japan; clinical studies for approvals in Australia and Europe are ongoing. » More on finanzen.net

Medacta has appointed Riccardo Fava as group VP investor relations, sustainability & media relations effective 1 October 2026. He reports directly to CEO Francesco Siccardi and will take responsibility for investor, analyst and media relations as well as for sustainability strategy and reporting. The company cites continued growth, particularly in the US, as the reason for the new appointment; the stock traded about 1 percent higher at times. » More on finanzen.net

Medacta reported currency-adjusted revenue growth of around 10% in H1 2026 to EUR 368m and an adjusted EBITDA of EUR 97m (currency-adjusted margin 27.8%). Gross margin fell to 65.2% and free cash flow turned negative at -EUR 18.6m due to inventory build-up and investments; operating cash flow also declined. Management confirmed the full-year guidance (currency-adjusted revenue growth 10–14% and margin improvement) and expects improvement in H2 supported by a US recovery, shipments to India and easier comparables. The stock fell 3.43% and traded near its 52-week low as investors highlighted weaker cash generation and margin trends. » More on de.investing.com

Medacta reports H1 2026 revenue of €368.0m (about +7%) and adjusted EBITDA of €97.4m (-1.4%); the margin fell to 26.5% from 28.7% a year earlier. Net profit declined to €41.9m, mainly because a one-off takeover gain from 2025 (Parcus Medical) did not recur. CEO Francesco Siccardi cited an unexpected slowdown in the US market and higher transport costs as headwinds; full-year targets remain confirmed with a revenue target of +10–14% and an adjusted EBITDA margin improvement of ~50 basis points, and medium-term annual revenue growth of 12–15% is targeted for 2024–2027. » More on finanzen.net

Medacta reports first-half group revenue of €368 million, which is 1% below analysts' expectations on a constant-currency basis (consensus €373 million). Constant-currency revenue growth was 9.7% versus an expected 11.5%, driven by strong gains in Asia‑Pacific (13.1%) and EMEA (10.0%), while North America grew only 6.6% on a constant-currency basis. Weaker performance was recorded in knee, spine, and shoulder and sports medicine; Medacta attributes the US slowdown in part to a sales reorganization in the spine division. The company confirms its full-year guidance of 10–14% constant-currency revenue growth and says it would need to achieve around 14.3% constant-currency growth in the second half to reach the midpoint. » More on de.investing.com